Genomma Opts for FRN

Genomma Opts for FRN


Given strong demand for floating-rate bonds as yields rise, Genomma Lab has opted for a floating-rate tranche over a 10-year fixed portion in its MXP2bn ($154m) domestic bond offering, according to people following the sale. It plans a 5-year floating rate bond sale as soon as Thursday, but may extend pricing to next week depending on market conditions. A deal will be the Mexican pharmaceutical and hygiene products company’s domestic market debut. Proceeds will be used for general corporate purp

Already have an account?

Free trial

Take a free two-week trial now for the latest news, data and market analysis.

Free Trial